Evidence map›Paper›PMID 41182464›Full record

ArticleEndocrine pathology2025

Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy.

Louis de Mestier, Thorvardur R Halfdanarson, Leonidas Apostolidis, Anna Koumarianou, Jorge Hernando, Rachel Riechelmann, Emily K Bergsland, Sara Cingarlini, Shagufta Shaheen, Joakim Crona and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Louis de MestierDepartment of Pancreatology and Digestive Oncology, Université Paris-Cité, Beaujon Hospital (APHP), Clichy, France. louis.demestier@aphp.fr.
Thorvardur R HalfdanarsonMayo Clinic Comprehensive Cancer Center, Rochester, MN, USA.
Leonidas ApostolidisDepartment of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Anna KoumarianouHematology Oncology Unit, Fourth Department of Internal Medicine, "Attikon" University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Jorge HernandoMedical Oncology Department, NET- VHIO Research Unit, Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Rachel RiechelmannAC Camargo Cancer Center, São Paulo, Brazil.
Emily K BergslandUniversity of California, San Francisco, San Francisco, CA, USA.
Sara CingarliniUniversity Trust of Verona, Verona, Italy.
Shagufta ShaheenDivision of Oncology, Stanford University, Stanford, CA, USA.
Joakim CronaUppsala Universitet, Uppsala, Sweden.
Simon KreutzfeldtDivision of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Osama MosalemMayo Clinic Florida, Jacksonville, FL, USA.
Taymeyah Al-ToubahH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Jérôme CrosDepartment of Pathology, Université Paris-Cité, Beaujon Hospital (APHP), Clichy, France.
Jonathan R StrosbergH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alkylating agent-based chemotherapy is one of the main treatment options for patients with metastatic pancreatic neuroendocrine tumors (PanNETs).However, it favors the acquisition of a hypermutator phenotype, suggesting a potential benefit of immunotherapy.We aimed to describe the efficacy of immunotherapy in an international retrospective cohort of patients with metastatic well-differentiated PanNETs pretreated with alkylating therapy. The primary endpoint was progression-free survival (PFS) and the main secondary endpoint was the radiological objective response rate (ORR). We explored the impact of tumor mutation burden (TMB) and mismatch repair deficiency (MMRd), and evaluated variables associated with PFS.We included 64 patients with heavily pretreated PanNETs (median Ki-67 28%). Among 51 PanNETs with mutational profiling, 37 (73%) were TMB

Indexed as

Antineoplastic Agents, AlkylatingImmunotherapyNeuroendocrine TumorsPancreatic NeoplasmsAdultAgedAged, 80 and overDNA Mismatch RepairFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedMutationRetrospective StudiesAntineoplastic Agents, AlkylatingImmune Checkpoint InhibitorsAlkylating chemotherapyImmune-checkpoint inhibitorsMetastasesPancreatic neuroendocrine tumorsProgression-free survival

Identifiers

PMID41182464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.